## Highlights of This Issue 6645

### SPECIAL FEATURES

#### CCR Translations

- **6647**
  - The Context of Blood Vessels and Response to VEGF-Targeted Therapy
  - Brian I. Rini
  - See related article, p. 6943

#### CCR Perspectives in Drug Approval

- **6650**
  - Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

#### CCR Drug Updates

- **6657**
  - Pralatrexate Pharmacology and Clinical Development
  - Enrica Marchi, Michael Mangone, Kelly Zullo, and Owen A. O'Connor

#### Molecular Pathways

- **6662**
  - Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma
  - Lorena Fontán and Ari Melnick

#### Perspectives

- **6669**
  - Anticipating the Clinical Use of Prognostic Gene Expression–Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?
  - Anita Sveen, Arild Nesbakken, Trude H. Aagesen, Marianne G. Guren, Kjell M. Tveit, Rolf L. Skothiem, and Ragnhild A. Lothe

### Review

- **6678**
  - Hepatocellular Carcinoma from an Immunologic Perspective
  - Tim F. Greten, Austin G. Duffy, and Firouzeh Korangy

### HUMAN CANCER BIOLOGY

- **6686**
  - Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
  - Rita Coutinho, Andrew James Clear, Andrew Owen, Andrew Wilson, Janet Matthews, Abigail Lee, Rute Alvarez, Maria Gomes da Silva, José Cabeça das, Maria Calaminici, and John G. Gribben

#### BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition


#### HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s

- Ling Li, Wenhua Tang, Xiaoqin Wu, David Karnak, Xiaojie Meng, Rachel Thompson, Xiaobo Hao, Yongmin Li, Xiaotan Q. Qiao, Jianyu Lin, James Fuchs, Diane M. Simeone, Zhi-Nan Chen, Theodore S. Lawrence, and Liang Xu

### CANCER THERAPY: PRECLINICAL

- **6716**
  - Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
  - Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Sagybek Manap, Linlin Xiao, Jiyuh Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Soledad Fernandez, and Peter J. Houghton
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Klein, Werner Scheuer, Romi Raemsch, Erica Lorenzon, Dirk Bernicke, Frank Herting, Sidney Yu, Huynh Hung The, Laurent Martarello, Christian Gassner, Kay-Gunnar Stubenrauch, Kate Munro, Hellmut G. Augustin, and Markus Thomas

Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response

Vanessa E. Zannella, Alan Dal Pra, Hala Muaddi, Trevor D. McKee, Shawn Stapleton, Jenna Sykes, Rachel Glicksman, Selim Chaib, Paul Zamiara, Michael Milesevic, Bradly G. Wouters, Robert G. Bristow, and Marianne Koritzinsky

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

Teresa Troiani, Erika Martinelli, Stefania Napolitano, Donata Vitagliano, Loretta Piia Ciaffreda, Sara Costantino, Floriana Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nappi, Raffaele De Palma, Elena D’Aiuto, Liberato Berrino, Roberto Bianco, and Fortunato Ciardiello

Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors

Krupa J. Patel, Carol Lee, Qian Tan, and Ian F. Tannock

The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo

Jih-Hsiang Lee, Kang-Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng-Tzu Weng, Yisong Wang, and Giuseppe Giacone

A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells

Isabel Puig, Irene Chicote, Stephan P. Tenbaum, Oriol Arqués, José Raúl Herance, Juan D. Gispert, José Jimenez, Stefania Landolfi, Karina Caci, Helena Allende, Leire Mendizábal, Débora Moreno, Ramón Charco, Eloy Espín, Alex Prat, Maria Elena Elez, Guillaume Argilès, Ana Vivancos, Josep Tabernero, Santiago Rojas, and Héctor G. Palmer

Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing P13K/AKT Signaling, Tumor Growth, and Metastasis

Ren Liu, Xiaoping Li, Wenming Guo, Yue Zhou, Shiuan Wei, Satyajit K. Mitra, Valery Krasnoperov, Dezheong Dong, Shuanglong Liu, Dan Li, Genyuang Zhu, Stan Louie, Peter S. Conti, Zibo Li, Amy S. Lee, and Parkash S. Gill

Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma


A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkin Lymphoma

Arutselvan Natarajan, Benjamin J. Hackel, and Sanjiv Sam Gambhir

Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas


Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma

The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy

Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ru-Ji Zhou, Ke-Da Yu, Yin Liu, and Zhi-Ming Shao

6853

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Haverty, Bianca Liederer, Xiaorong Liang, Robert L. Vauch, Thomas O'Brien, Richard Bourgon, Hartmut Koeppe, and Lisa D. Belmont

6912

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer


6924

Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis

Carlo Palmieri, John R. Fullarton, and Janet Brown

6863

Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia

Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Raffeld, and Maryalice Stetler-Stevenson

6873

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W. Kweek, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemeister, Jie Xin Zhang, Shouhao Zhou, Lei Feng, and Anas Younes

6882

Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer


6891

Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremitity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates


6902

Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xian Sheng, Li Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, and Jun Guo

6935

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy


6957

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hediy L. Kindler, Richard M. Goldberg, Alan P. Venook, and Herbert I. Hurwitz for the Alliance for Clinical Trials in Oncology

6943

See related article, p. 6647

PDGFRA

The Journal of Clinical and Translational Research v www.aacrjournals.org

on April 29, 2017. © 2013 American Association for Cancer Research.
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial


Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodriguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andres Cervantes, Josep Tabernero, Premal Patel, and Jose Baselga

Acknowledgment to Reviewers

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows drug distribution in a solid tumor derived from breast cancer cells in a mouse xenograft. Immunohistochemical staining shows enhanced doxorubicin distribution around functional blood vessels in mice pretreated with pantoprazole. For details, see the article by Patel and colleagues on page 6766 of this issue.